AbbVie (NYSE: ABBV) reported third-quarter 2020 financial results before the regular trading hours on Friday. The pharmaceutical behemoth reported Q3 revenue of $12.9 billion, which surpassed the Wall Street consensus. Net earnings of $2.83 per share were also better than the target that analysts had projected.
ABBV shares gained 1.4% immediately following the announcement. The stock has slipped 10% since the beginning of this year.
AbbVie’s flagship arthritis drug Humira reported net revenues of $5.140 billion, which was 4% more than last year. While sales increased 7.7% in the US, international markets saw a 9% decrease due to competition from biosimilars.
S&P Global (NYSE: SPGI), a leading provider of financial intelligence solutions, reported strong earnings growth…
Fiserv Inc. (NASDAQ: FISV) reported its fourth quarter 2025 earnings results today. Revenue increased 1%…
Incyte achieved total revenue of $5.14 billion for the full year 2025, a 21% year-over-year…
CVS Health Corporation (NYSE: CVS) reported record full-year 2025 consolidated revenues of $402.1 billion, a…
Healthcare solutions company CVS Health Corporation (NYSE: CVS) on Monday reported an increase in revenues…
The industrial materials manufacturer reported flat fourth-quarter sales and a full-year organic growth rate of…
